Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2010-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00280-009-1101-yPMID 19714332
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analysis of BNP7787 thiol-disulfide exchange reactions in phosphate buffer and human plasma using microscale electrochemical high performance liquid chromatography.

  2009influential reference
• Crystal structure of the gamma-glutamyltranspeptidase precursor protein from Escherichia coli. Structural changes upon autocatalytic processing and implications for the maturation mechanism.

  2007cited by this paper
• Cisplatin Nephrotoxicity: A Review

  2007cited by this paper
• Crystal structures of gamma-glutamyltranspeptidase from Escherichia coli, a key enzyme in glutathione metabolism, and its reaction intermediate.

  2006cited by this paper
• Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults.

  2005cited by this paper
• Gamma-glutamyl transpeptidase substrate specificity and catalytic mechanism.

  2005influential reference
• Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule

  2005influential reference
• Acceleration of Glutathione Efflux and Inhibition of γ-Glutamyltranspeptidase Sensitize Metastatic B16 Melanoma Cells to Endothelium-induced Cytotoxicity*

  2005cited by this paper
• Cisplatin nephrotoxicity

  2004cited by this paper
• Acute effects of cis-diamminedichloroplatinum (CDDP) on renal function

  2004cited by this paper
• Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.

  2004cited by this paper
• Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats

  2004cited by this paper
• Role of cysteine S-conjugate beta-lyase in the metabolism of cisplatin.

  2003cited by this paper
• Cisplatin nephrotoxicity.

  2003cited by this paper
• Role of Cysteine S-Conjugate β-Lyase in the Metabolism of Cisplatin

  2003cited by this paper
• Quantification of mesna and total mesna in kidney tissue by high-performance liquid chromatography with electrochemical detection.

  2003cited by this paper
• The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG

  2003cited by this paper
• New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent

  2003influential reference
• Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy

  2003cited by this paper
• Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells.

  2003influential reference
• Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector.

  2003cited by this paper
• Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites

  2003cited by this paper
• Simultaneous determination of intact cisplatin and its metabolite monohydrated cisplatin in human plasma.

  2002cited by this paper
• Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice.

  2002influential reference
• BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.

  2002cited by this paper
• Anticancer Drug—Induced Kidney Disorders

  2001cited by this paper
• Chemical-induced nephrotoxicity mediated by glutathione S-conjugate formation.

  2001cited by this paper
• Quantification of BNP7787 (dimesna) and its metabolite mesna in human plasma and urine by high-performance liquid chromatography with electrochemical detection.

  2001cited by this paper
• (cid:2) -Glutamyl Transpeptidase-Deficient Mice Are Resistant to the Nephrotoxic Effects of Cisplatin

  2001cited by this paper
• Status of glutathione and other thiols and disulfides in human plasma.

  2000cited by this paper
• Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo.

  1999cited by this paper
• Organ-specific carcinogenicity of haloalkenes mediated by glutathione conjugation

  1999cited by this paper
• Current status of platinum-based antitumor drugs.

  1999cited by this paper
• Gamma-glutamyl transpeptidase-dependent iron reduction and LDL oxidation--a potential mechanism in atherosclerosis.

  1999cited by this paper
• Grand RoundsThe University of Texas Health Science Center at San Antonio

  1999cited by this paper
• Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin.

  1999cited by this paper
• gamma-Glutamyl transpeptidase, a glutathionase: its expression and function in carcinogenesis.

  1998cited by this paper
• Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.

  1998cited by this paper
• Glutathione-dependent bioactivation of haloalkenes.

  1998cited by this paper
• Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application.

  1997cited by this paper
• Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.

  1996cited by this paper
• Cisplatin nephrotoxicity: inhibition of gamma-glutamyl transpeptidase blocks the nephrotoxicity of cisplatin without reducing platinum concentrations in the kidney.

  1996influential reference
• Future development of amifostine in cancer treatment.

  1996cited by this paper
• Measurement of gamma-glutamyl transpeptidase and gamma-glutamylcysteine synthetase activities in cells.

  1995cited by this paper
• [7] Measurement of γ-glutamyl transpeptidase and γ-glutamylcysteine synthetase activities in cells

  1995cited by this paper
• Cisplatin nephrotoxicity.

  1994cited by this paper
• Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity.

  1994influential reference
• Formation and fate of nephrotoxic and cytotoxic glutathione S-conjugates: cysteine conjugate beta-lyase pathway.

  1994cited by this paper
• Homocysteine and other thiols determined in plasma by HPLC and thiol-specific postcolumn derivatization.

  1993cited by this paper
• Bioactivation of nephrotoxins and renal carcinogens by glutathione S-conjugate formation.

  1993cited by this paper
• Control of the nephrotoxicity of cisplatin by clinically used sulfur-containing compounds.

  1992cited by this paper
• High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.

  1992cited by this paper
• Amelioration by ascorbic acid of cisplatin-induced injury in cultured renal epithelial cells.

  1991cited by this paper
• Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate.

  1990cited by this paper
• Regulation of cellular glutathione.

  1989cited by this paper
• Mesna--a short review.

  1987cited by this paper
• Histopathological Study of Human Cisplatin Nephropathy

  1986cited by this paper
• Gamma-glutamyl transpeptidase--its role in hepatocarcinogenesis.

  1985cited by this paper
• Some effects of combination chemotherapy with cis‐platinum on renal function in patients with nonseminomatous testicular carcinoma

  1983cited by this paper
• Mechanism of cisplatin nephrotoxicity.

  1983cited by this paper
• Renal transport and disposition of Na‐2‐mercaptoethane sulfonate disulfide (Dimesna) in the rat

  1982cited by this paper
• γ-Glutamyl transpeptidase: catalytic, structural and functional aspects

  1981cited by this paper
• Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations.

  1980cited by this paper
• Mechanism of cis-platinum nephrotoxicity: I. Effects of sulfhydryl groups in rat kidneys.

  1980cited by this paper
• A sensitive fluorimetric assay for γ-glutamyl transferase

  1979cited by this paper
• A sensitive fluorimetric assay for gamma-glutamyl transferase.

  1979cited by this paper
• Platinum nephrotoxicity.

  1978cited by this paper
• Interrelationships between the binding sites for amino acids, dipeptides, and gamma-glutamyl donors in gamma-glutamyl transpeptidase.

  1977cited by this paper
• The renal pathology in clinical trials of Cis‐platinum (II) diamminedichloride

  1977cited by this paper
• Utilization of L-cystine by the gamma-glutamyl transpeptidase-gamma-glutamyl cyclotransferase pathway.

  1975cited by this paper
• Interaction of gamma-glutamyl transpeptidase with amino acids, dipeptides, and derivatives and analogs of glutathione.

  1974cited by this paper
• Platinum nephrotoxicity

  1974cited by this paper

• Protective effect of Phytochemicals against Cisplatin induced Nephrotoxicity

  2021cites this paper
• Cisplatin chemotherapy and renal function.

  2021influential citation
• Amlodipine alleviates cisplatin-induced nephrotoxicity in rats through gamma-glutamyl transpeptidase (GGT) enzyme inhibition, associated with regulation of Nrf2/HO-1, MAPK/NF-κB, and Bax/Bcl-2 signaling

  2020cites this paper
• Bismuth Porphyrin Antagonizes Cisplatin-Induced Nephrotoxicity via Unexpected Metallothionein-Independent Mechanisms

  2020cites this paper
• Antioxidant Supplementation in the Treatment of Neurotoxicity Induced by Platinum-Based Chemotherapeutics—A Review

  2020cites this paper
• Cytoprotective Agents to avoid Chemotherapy Induced Sideeffects on Normal Cells: A Review.

  2019cites this paper
• Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity

  2019cites this paper
• Clinical Evaluation of Tavocept to Decrease Diuresis Time and Volume in Dogs with Bladder Cancer Receiving Cisplatin

  2017cites this paper
• Carvedilol protects the kidneys of tumor-bearing mice without impairing the biodistribution or the genotoxicity of cisplatin.

  2016cites this paper
• Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy

  2016cites this paper
• Enzymatic and non-enzymatic mechanisms of dimesna metabolism

  2015influential citation
• The control of hyperhomocysteinemia through thiol exchange mechanisms by mesna

  2014cites this paper
• Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update

  2012cites this paper
• Applications d'une modulation pharmacologique des dérives des formes réactives de l'oxygène pour une optimisation thérapeutique des patients traités par chimiothérapie

  2012cites this paper
• Tavocept (BNP7787) : a novel chemoprotector/sensitizer and radioprotector/sensitizer

  2011cites this paper
• Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer

  2011cites this paper
• Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N

  2011cites this paper
• The effect of sildenafil on cisplatin nephrotoxicity in rats.

  2011cites this paper
• Accumulation of BNP7787 in human renal proximal tubule cells.

  2011cites this paper
• Pharmacokinetics and Therapeutic Uses of Mesna

  2010cites this paper
• Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer

  2010cites this paper
• BNP7787-Mediated Modulation of Paclitaxel- and Cisplatin-Induced Aberrant Microtubule Protein Polymerization In vitro

  2010cites this paper